top of page

iQure Pharma Attending JPM Week in San Francisco — January 8-12, 2024

Princeton, NJ, December 22, 2023 ─ iQure Pharma Inc. (iQure), a U.S.-based pre-clinical drug discovery company focusing on central nervous system (CNS) disorders, is attending the 42nd Annual J.P. Morgan Health Care Conference, JPM Week, in January 2024.


iQure’s portfolio of treatments in Epilepsy, Pain and other neurodegenerative diseases has had a number of positive developments in the last year. As a result, iQure Pharma has intensified its focus in the areas of strategic partnering and fundraising, targeting clinical development of iQ-007 in 2024. Pawel Zolnierczyk, CEO and Henk de Wilde, COO and R&D Director, will be participating in JPM Week to further explore strategic collaborations with pharma and expand current fundraising activities.


“These are exciting times for iQure with very promising market traction and significant interest from pharma for both of our assets,” said iQure CEO Pawel Zolnierczyk. “The recent oversubscription of our Series A round, validates iQure Pharma’s innovative approach to glutamate clearance. We remain dedicated to our mission of improving lives of patients living with neurological conditions.


iQure's leading compound, iQ-007, is a neuromodulator targeting toxic levels of glutamate in the synaptic cleft. An elevated level of glutamate leads to neurotoxicity and ultimately to neural degeneration. iQ-007 operates by a Positive Allosteric Modulation of Excitatory Amino Acid Transporter 2 (EAAT2 PAM), which is responsible for up to 90% of glutamate uptake. The company’s pioneering glutamate clearance platform is expected to foster the development of new treatments for a wide range of neuro disorders, including epilepsy, stroke, neuropathic pain, Parkinson’s, Alzheimer’s, and Traumatic Brain Injury. These treatments are aimed at delivering effective solutions without the common side-effects associated with CNS therapeutics.


For those interested in meeting with iQure Pharma in San Francisco during JPM Week, please register here:



About iQure Pharma:

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies based on a revolutionary glutamate-clearance platform for treating neurodegenerative conditions including neuro-inflammation.


25 views0 comments

Recent Posts

See All


bottom of page